infused < infusion < infusional

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by infusion

Number of relevant bibliographic references: 25.
[0-20] [0 - 20][0 - 25][20-24][20-40]

Ident.	Authors (with country if any)	Title
000157 (2020)	Jingsheng Hua [République populaire de Chine] ; Weiqing Qian [République populaire de Chine] ; Xiaoxia Wu [République populaire de Chine] ; Lili Zhou [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Suning Chen [République populaire de Chine] ; Jian Zhang [République populaire de Chine] ; Huiying Qiu [République populaire de Chine]	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
000271 (2020)	Gabriella Bottari [Italie] ; Pietro Merli [Italie] ; Isabella Guzzo [Italie] ; Francesca Stoppa [Italie] ; Annalisa Ruggeri [Italie] ; Matteo Di Nardo [Italie] ; Francesca Del Bufalo [Italie] ; Federica Galaverna [Italie] ; Cecchetti Corrado [Italie] ; Franco Locatelli [Italie]	Multimodal Therapeutic Approach of Cytokine Release Syndrome Developing in a Child Given Chimeric Antigen Receptor-Modified T Cell Infusion
000729 (2019)	Michael R. Bishop [États-Unis] ; Richard T. Maziarz [États-Unis] ; Edmund K. Waller [États-Unis] ; Ulrich J Ger [Autriche] ; Jason R. Westin [États-Unis] ; Joseph P. Mcguirk [États-Unis] ; Isabelle Fleury [Canada] ; Harald Holte [Norvège] ; Peter Borchmann [Allemagne] ; Christopher Del Corral [États-Unis] ; Ranjan Tiwari [Inde] ; Özlem Anak [Suisse] ; Rakesh Awasthi [États-Unis] ; Lida Pacaud [États-Unis] ; Vadim V. Romanov [États-Unis] ; Stephen J. Schuster [États-Unis]	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion
000757 (2019)	Macarena C. Cáceres [Espagne] ; Jorge Guerrero-Martín [Espagne] ; Demetrio Pérez-Civantos [Espagne] ; Patricia Palomo-L Pez [Espagne] ; Juan Ignacio Delgado-Mingorance [Espagne] ; Noelia Durán-G Mez [Espagne]	The importance of early identification of infusion-related reactions to monoclonal antibodies
000825 (2019)	Lingzhi Yan ; Jingjing Shang ; Xiaolan Shi ; Huizhu Kang ; Wei Liu ; Nan Xu ; Yong Liu ; Guanghua Chen ; Liqing Kang ; Feiran Gong ; Fang Tang ; Lei Yu ; Depei Wu ; Chengcheng Fu	Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells
000978 (2019)	Xia Xiao [République populaire de Chine] ; Xiaoyuan He [République populaire de Chine] ; Qing Li [République populaire de Chine] ; Huan Zhang [République populaire de Chine] ; Juanxia Meng [République populaire de Chine] ; Yanyu Jiang [République populaire de Chine] ; Qi Deng [République populaire de Chine] ; Mingfeng Zhao [Oman]	Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
000F21 (2019)	Joost F. Swart ; Sytze De Roock ; Rutger A J. Nievelstein [Pays-Bas] ; Ineke C M. Slaper-Cortenbach [Pays-Bas] ; Jaap J. Boelens ; Nico M. Wulffraat	Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients.
001205 (2018)	Jean-Hugues Salmon ; Jeanne-Marie Perotin ; Jacques Morel [France] ; Moustapha Dramé ; Alain Cantagrel [France] ; Liana Euller Ziegler ; Philippe Ravaud [France] ; Jean Sibilia ; Isabelle Pane [France] ; Xavier Mariette ; Jacques-Eric Gottenberg [France]	Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
001260 (2018)	Surabhi S. Vinod [États-Unis] ; Annelle B. Reed [États-Unis] ; Jamelle Maxwell [États-Unis] ; Randy Q. Cron [États-Unis] ; Matthew L. Stoll [États-Unis]	Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.
001841 (2017)	Yuhong Chen [République populaire de Chine] ; Yifei Cheng [République populaire de Chine] ; Pan Suo [République populaire de Chine] ; Chenhua Yan [République populaire de Chine] ; Yu Wang [République populaire de Chine] ; Yao Chen [République populaire de Chine] ; Wei Han [République populaire de Chine] ; Lanping Xu [République populaire de Chine] ; Xiaohui Zhang [République populaire de Chine] ; Kaiyan Liu [République populaire de Chine] ; Lungji Chang [République populaire de Chine] ; Lei Xiao [République populaire de Chine] ; Xiaojun Huang [République populaire de Chine]	Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
001858 (2017)	Jordana Schmier [États-Unis] ; Kristine Ogden [États-Unis] ; Nancy Nickman [États-Unis] ; Michael T. Halpern [États-Unis] ; Mary Cifaldi [États-Unis] ; Arijit Ganguli [États-Unis] ; Yanjun Bao [États-Unis] ; Vishvas Garg [États-Unis]	Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.
001C02 (2016)	H M Lindegaard [Danemark] ; P. Johansen [Danemark] ; G. Gröndal [Islande] ; E C Jensen [Danemark] ; L. Juul [Danemark] ; A M Schlemmer [Danemark] ; B. Agular [Danemark] ; Imj Hansen [Danemark]	Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious.
001D76 (2016)	Andrew K. L. Goey [États-Unis] ; Tristan M. Sissung [États-Unis] ; Cody J. Peer [États-Unis] ; Jane B. Trepel [États-Unis] ; Min-Jung Lee [États-Unis] ; Yusuke Tomita [États-Unis] ; Sheryl Ehrlich [États-Unis] ; Christine Bryla [États-Unis] ; Sanjeeve Balasubramaniam [États-Unis] ; Richard Piekarz [États-Unis] ; Seth M. Steinberg [États-Unis] ; Susan E. Bates [États-Unis] ; William D. Figg [États-Unis]	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48‐hour continuous infusion in patients with cancer
002067 (2015)	Ciara L. Freeman [Royaume-Uni] ; Franck Morschhauser [France] ; Laurie Sehn [Canada] ; Mark Dixon [Royaume-Uni] ; Richard Houghton [Royaume-Uni] ; Thierry Lamy [France] ; Günter Fingerle-Rowson [Suisse] ; Elisabeth Wassner-Fritsch [Suisse] ; John G. Gribben [Royaume-Uni] ; Michael Hallek [Allemagne] ; Gilles Salles [France] ; Guillaume Cartron [France]	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
002672 (2013)	Milan Fiala [États-Unis] ; Mathew T. Mizwicki ; Rachel Weitzman ; Larry Magpantay ; Norihiro Nishimoto	Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients.
002B19 (2013)	F. A. Aeschlimann ; K. D. Hofer ; E. Cannizzaro ; S. Schroeder ; R. Lauener ; R. K. Saurenmann [Suisse]	SAT0461 Infliximab Treatment in Children: Frequency of Infusion Reactions and Role of Desensitization
002E03 (2013)	J. H. Salmon ; P. Ravaud [France] ; T. Bardin ; P. Cacoub [France] ; A. Cantagruel [France] ; B. Combe [France] ; M. Dougados [France] ; R.-M. Flipo ; B. Godeau ; L. Guillevin [France] ; X. Le Loët ; E. Hachulla ; T. Schaeverbeke ; J. Sibilia [France] ; I. Pane [France] ; G. Baron ; X. Mariette [France] ; J.-E. Gottenberg [France]	FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry
002E46 (2013)	M. Alperi ; M. Belmonte-Serrano ; P. Lluch ; P. Trenor ; J. Calvo-Alen ; E. García-Fernández ; A. Olivé ; J. Tinture ; A. Romero [Espagne]	FRI0195 Tocilizumab infusion performed in 31 minutes in patients with rheumatoid arthritis is safe and well tolerated
003098 (2013)	M. Can [Turquie] ; F. Alibaz-Öner [Turquie] ; S. Öner [Turquie] ; P. Atagunduz [Turquie] ; N. Inanc [Turquie] ; H. Direskeneli [Turquie]	AB0558 Accelerated infusion rates of RITUXIMAB is well-tolerated and safe in rheumatology practice: A single center experience
003231 (2013)	C. H. Pritchard ; M. W. Greenwald ; J. M. Kremer ; N. B. Gaylis ; S. Zlotnick [États-Unis] ; C. Chung [États-Unis] ; B. Jaber [Suisse] ; W. Reiss [États-Unis]	AB0302 Results from the rate-ra study: a multicenter, open-label, single-arm study to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with rheumatoid arthritis
003449 (2012)	Louisa Voight [Australie]	Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "infusion" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "infusion" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    infusion
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021